Published on 02/12/2025

SUS Validation Files: What to Keep at the Site vs Vendor

In the pharmaceutical industry, specifically in the domains of extractables and leachables (E&L) and packaging qualification, the validation of single-use systems (SUS) such as filters and bags has gained significant attention. Actual practice must be grounded in solid regulatory compliance and scientific rationale. This tutorial will explore the critical components of SUS validation files, clarifying what documentation should be retained at the site versus what may be kept with vendors. This understanding is vital for conducting effective E&L risk assessments, meeting regulatory expectations, and ensuring patient safety.

Understanding Extractables and Leachables in Single-Use Systems

Extractables and leachables refer to the chemical compounds that can migrate from materials used in drug packaging and delivery into the drug product itself. In the context of single-use systems, including filters and bags, it is essential to assess these potential contaminants as they can adversely affect the drug’s safety and efficacy. The FDA and EMA have set forth guidelines that mandate a thorough investigation into E&L to safeguard patient health.

During this assessment, two important thresholds are considered: the analytical evaluation threshold (AET) and the dose-based threshold (DBT). The AET is the minimum concentration at which a leachable can be considered significant and should be identified. The DBT is determined for specific compounds based on the dosage of the drug, using toxicity data, ensuring safety for patients. Both thresholds are critical for establishing a robust E&L risk assessment that complies with FDA process validation and EU GMP Annex 1 requirements.

Key Concepts in SUS Validation

Validation of single-use systems includes several subcategories that need to be meticulously documented. The following elements should be part of the validation process when addressing E&L:

• Risk Assessment: A comprehensive E&L risk assessment should be conducted to identify potential risks associated with single-use systems.
• Testing Protocols: Develop protocols for testing and characterizing E&L within the context of the intended use of the product.
• Documentation of Findings: Document all findings from testing, including analytical data, methodologies, and outcomes.
• Regulatory Compliance: Ensure all testing conforms to applicable regulatory standards and guidelines, such as those from the EMA and the PQRI guidelines.

What Documentation to Keep at the Site

Documentation retained onsite ensures that the facility can demonstrate compliance during inspections and audits. Given its critical nature, the following categories of documents should be preserved:

1. Validation Protocols and Reports

All protocols used for the validation of SUS should be kept on-site, including the results and reports generated from these datasets. This documentation forms the backbone of your validation process and should include:

• Validation study protocols detailing the objectives, methodologies, and acceptance criteria.
• Raw data, charts, and figures summarizing the findings of each validation study.
• A summary report correlating the test results with the pre-established criteria.

2. E&L Testing and Analytical Methods

Consistent documentation of E&L testing is paramount. Ensure you retain documents that provide detailed descriptions of:

• The analytical methods employed for extractables and leachables evaluation.
• The results of testing against the established AET and DBT values.
• Any deviation or modification of the methodologies used during the studies.

3. Training and Personnel Credentials

The site should also maintain records of training for personnel conducting the E&L risk assessment and validation. Key records include:

• Training certificates and qualifications of staff involved in validation activities.
• Evidence of routine training updates on regulatory changes and validation practices.

What Documentation to Keep with the Vendor

While certain documents should reside at the site, others can be responsibly maintained by the vendor. These include items that relate directly to their proprietary processes and product characteristics.

1. Vendor Verification and Documentation

For vendors, it is essential to retain documentation associated with their own validation processes, including:

• Certificates of analysis for materials and components utilized in manufacturing their products.
• Vendor validation studies demonstrating their own E&L assessments and results.
• Documentation of compliance with industry standards, including GMP and specific USP guidelines (e.g., USP CCI guidelines).

2. Specifications and Drawings

Ensure that your vendors hold onto updated specifications, which should encompass:

• Current specifications that define the performance and safety criterion of the filters and bags used.
• Design drawings that illustrate the single-use system’s assembly and configuration.

3. Audit Reports and Corrective Actions

Vendor audit reports and any corrective actions undertaken should also remain with the vendor. Important aspects include:

• Summary reports from periodic audits conducted to assess vendor compliance with agreed standards.
• Records of any corrective actions taken based on audit outcomes.

Risk Mitigation Strategies in SUS Validation

Effective risk mitigation strategies are essential for ensuring the integrity of the pharmaceutical product and minimizing the impact of potential leachables. The following strategies should be systematically applied within the framework of E&L assessments:

1. Performing a Comprehensive E&L Risk Assessment

The first line of defense is conducting a detailed E&L risk assessment. This assessment involves:

• Identifying materials used in the manufacturing of filters and bags.
• Assessing known leachables and potential risks associated with each material.
• Utilizing existing databases for AET and DBT calculations relevant to your specific product scenarios.

2. Routine Calibration of Analytical Equipment

The precision and accuracy of analytical methods are vital in E&L evaluations. To achieve this:

• Implement a routine calibration program for analytical instruments used in E&L evaluations.
• Document all calibrations and maintain a schedule of upcoming calibration events.

3. Continuous Monitoring and Re-evaluation

Following initial validations, manufacturers should incorporate continuous monitoring practices. This includes:

• Periodic re-evaluation of E&L risk based on manufacturing changes or product redesigns.
• Updating documentation accordingly to reflect new findings or updates in regulatory guidelines.

Conclusion and Best Practices for E&L Documentation

When managing SUS validation files, the distinction between documentation retained at the site and that which can be stored with the vendor is crucial in ensuring regulatory compliance and patient safety. Following a structured approach as described enhances the likelihood of successful inspections by regulatory bodies such as the FDA and EMA. By conducting thorough E&L risk assessments, maintaining robust documentation, and collaborating with vendors effectively, pharmaceutical professionals can safeguard their products while aligning with cGMP expectations.

In summary, the best practices highlighted in this guide serve not just as compliance checkboxes but as foundational elements of a quality management system (QMS) entrenched in proactive risk management for extractables and leachables in single-use systems.